1Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090-1101. 被引量：1
2Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type I diabetes[J]. Diabetes, 2004, 53(6): 1614-1620. 被引量：1
3Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience[J]. Expert Opin Pharmacother, 2006, 7(3): 325-343. 被引量：1
4McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long- acting agent for the management of type 1 and 2 diabetes mellitus[J]. Drugs, 2001, 61(11): 1599-1624. 被引量：1
5Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long- acting insulin analog glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000, 23(5): 644-649. 被引量：1
6Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies[J]. Diabetes Obes Metab, 2007, 9(5): 648-659. 被引量：1
7Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro[J], Diabetes, 2000, 49(12): 2142-2148. 被引量：1
8Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites[J]. Diabetes Care, 2000, 23(6): 813-819. 被引量：1
9Heise T, Bott S, Rave K, et al. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with type 1 diabetes[]}. Diabet Med, 2002, 19(6): 490-495. 被引量：1
2DeFronzo RA,Tobin JD,Andres R.Glucose clamp technique:a method for quantifying insulin secretion and resistance.Am J Physiol,1979,237:E214-E223. 被引量：1
3Ipp E,Sinai Y,Bar-Oz B,et al.Somatostatin impairs clearance of exogenous insulin in humans.Diabetes,1987,36:673-677. 被引量：1
4Heinemann L,Linkeschova R,Rave K,et al.Time-action profile of the long-acting insulin analog insulin glargine(HOE901)in comparison with those of NPH insulin and placebo.Diabetes Care,2000,23:644-649. 被引量：1
5Lepore M,Kurzhals R,Pampanelli S,et al.Pharmacokinetics and dynamics of s.c.injection of the long-acting insulin glargine(HOE901)in T1DM.Diabetes,1999,48:A97. 被引量：1
6Nicole L,Timothy HR,Rossa C,et al.Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays.Clinical Chemistry,2004,50:257-259. 被引量：1
1Bretzel RC, Eekhard M, Landgraf W, et al. Initiating insulin theraphy in type 2 diabetic patients failing on oral hypoglyeemie agents:basal or prandial insulin the APOLLO trial and beyond [ J ]. Diabetes Care, 2009,32(12) :260 -265. 被引量：1
